Cargando…

Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers

BACKGROUND: The aim of the study was to explore Fc mutations of a humanised anti-Lewis-Y antibody (IgG1) hu3S193 as a strategy to improve therapeutic ratios for therapeutic payload delivery. METHODS: Four hu3S193 variants (I253A, H310A, H435A and I253A/H310A) were generated via site-directed mutagen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burvenich, Ingrid J. G., Lee, Fook-Thean, O’Keefe, Graeme J., Makris, Dahna, Cao, Diana, Gong, Sylvia, Rigopoulos, Angela, Allan, Laura C., Brechbiel, Martin W., Liu, Zhanqi, Ramsland, Paul A., Scott, Andrew M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796444/ https://www.ncbi.nlm.nih.gov/pubmed/26983636 http://dx.doi.org/10.1186/s13550-016-0180-0

Ejemplares similares

l-Tyrosine Confers Residualizing Properties to a d-Amino Acid-Rich Residualizing Peptide for Radioiodination of Internalizing Antibodies
por: Lee, Fook T., et al.
Publicado: (2016)

Molecular imaging of T cell co-regulator factor B7-H3 with (89)Zr-DS-5573a
por: Burvenich, Ingrid Julienne Georgette, et al.
Publicado: (2018)

In Vitro and In Vivo Evaluation of (89)Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy
por: Burvenich, Ingrid J.G., et al.
Publicado: (2016)

(212)Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint
por: Yong, K J, et al.
Publicado: (2013)

Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target
por: Sabanathan, Dhanusha, et al.
Publicado: (2021)

Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts
por: Yong, Kwon Joong, et al.
Publicado: (2016)

Immunostimulatory effects of radioimmunotherapy
por: Constanzo, Julie, et al.
Publicado: (2022)

Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin
por: Gan, Hui K, et al.
Publicado: (2021)

Pretargeted Molecular Imaging and Radioimmunotherapy
por: Goldenberg, David M., et al.
Publicado: (2012)

Radioimmunotherapy: a brief overview
por: Ng, DCE
Publicado: (2006)

Is radioimmunotherapy a 'magic bullet'?
por: Kim, Sung-Hyun
Publicado: (2012)

Improvement of Radioimmunotherapy Using Pretargeting
por: Frampas, Eric, et al.
Publicado: (2013)

Trial Watch: Anticancer radioimmunotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

A Possible Role for Metallic Ions in the Carbohydrate Cluster Recognition Displayed by a Lewis Y Specific Antibody
por: Farrugia, William, et al.
Publicado: (2009)

The $^{191,193}$Hg and $^{191,193}$Au positon decays
por: Vieu, C, et al.
Publicado: (1976)

Quantitative intratumoural microdistribution and kinetics of (131)I-huA33 antibody in patients with colorectal carcinoma
por: Ciprotti, Marika, et al.
Publicado: (2014)

Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors
por: Cimini, Andrea, et al.
Publicado: (2020)

Combination Radioimmunotherapy Strategies for Solid Tumors
por: Zaheer, Javeria, et al.
Publicado: (2019)

Editorial: Radioimmunotherapy—Translational Opportunities and Challenges
por: Gaipl, Udo S., et al.
Publicado: (2020)

Dynamics of an Antitumour Model with Pulsed Radioimmunotherapy
por: Wang, Gang, et al.
Publicado: (2022)

Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways
por: Greening, David W., et al.
Publicado: (2015)

Correction: Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways
por: Greening, David W., et al.
Publicado: (2016)

Radioimmunotherapy of malignancy using antibody targeted radionuclides.
por: Cobb, L. M., et al.
Publicado: (1986)

Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections
por: Dadachova, Ekaterina, et al.
Publicado: (2011)

Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma
por: Bodet-Milin, Caroline, et al.
Publicado: (2013)

Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET
por: Kim, Jin Su
Publicado: (2016)

Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy
por: Uccelli, Licia, et al.
Publicado: (2017)

Radioimmunotherapy: future prospects from the perspective of brachytherapy
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Radioimmunotherapy in colorectal cancer treatment: present and future
por: Shi, Jingyi, et al.
Publicado: (2023)

LIN92#19.3
Publicado: (1993)

AB193. Rectourethral fistula
por: Jiang, Hai
Publicado: (2016)

Health Tract, No. 193: Bread
Publicado: (1865)

Health Tract, No. 193: Bread
Publicado: (1864)

Radioimmunotherapy of micrometastases in lung with vascular targeted(213)Bi
por: Kennel, S J, et al.
Publicado: (1999)

Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy.
por: Bosslet, K., et al.
Publicado: (1991)

Chemotherapy Synergizes with Radioimmunotherapy Targeting La Autoantigen in Tumors
por: Al-Ejeh, Fares, et al.
Publicado: (2009)

Repeated Intraperitoneal α-Radioimmunotherapy of Ovarian Cancer in Mice
por: Elgqvist, Jörgen, et al.
Publicado: (2010)

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer
por: Kraeber–Bodéré, F., et al.
Publicado: (2009)

A pretargeting system for tumor PET imaging and radioimmunotherapy
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2015)

Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma
por: Westrøm, Sara, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_16h3pm58ugqq1jlt1hc0bgmbco